[Clinical Features and Prognosis of Patients with Diffuse Large B-Cell Lymphoma of the Breast].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2024-10-01 DOI:10.19746/j.cnki.issn.1009-2137.2024.05.016

Jin-Jie Wei, Lie-Yang Wang, Zhi-Qiang Zhao, Li-Ping Su

{"title":"[Clinical Features and Prognosis of Patients with Diffuse Large B-Cell Lymphoma of the Breast].","authors":"Jin-Jie Wei, Lie-Yang Wang, Zhi-Qiang Zhao, Li-Ping Su","doi":"10.19746/j.cnki.issn.1009-2137.2024.05.016","DOIUrl":null,"url":null,"abstract":"Objective: To explore the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) of the breast.Methods: The clinical data of 28 DLBCL patients admitted to Shanxi Provincial Cancer Hospital from January 2013 to January 2023 were retrospectively analysed, including 13 cases of primary breast DLBCL (PB-DLBCL) and 15 cases of secondary breast DLBCL (SB-DLBCL), and the data of their clinical manifestations, laboratory tests, pathological examinations, treatment protocols, and follow-up were statistically analyzed.Results: There were significant differences in IPI score, LDH level and β2- microglobulin between PB-DLBCL and SB-DLBCL patients (P < 0.05). Among the 23 patients with breast DLBCL who received regular treatment, 13 patients achieved complete remission (9 patients with PB-DLBCL and 4 patients with SB-DLBCL) after initial treatment. By the end of follow-up, 11 patients relapsed or progressed (5 patients with PB-DLBCL and 6 patients with SB-DLBCL) and 9 patients died (3 patients with PB-DLBCL and 6 patients with SB-DLBCL). The 5-year OS rate was (75.0±15.3)% in PB-DLBCL group and (32.3±17.1)% in SB-DLBCL group. The 5-year PFS rate was （59.1±19.8）% in PB-DLBCL and 0% in SB-DLBCL group. The 5-year OS rate and PFS rate of PB-DLBCL patients were higher than those of SB-DLBCL patients (P < 0.05); the 5-year OS rate of the combined central preventive treatment group was higher than that of the chemotherapy group (P < 0.05).Conclusion: Breast DLBCL is divided into two categories: PB-DLBCL and SB-DLBCL. Compared with SB-DLBCL, PB-DLBCL has the characteristics of lower IPI score, LDH, and β2-microglobulin levels. PB-DLBCL patients have a longer survival period. In addition, the prognosis of patients receiving central preventive treatment is more optimistic.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"32 5","pages":"1407-1413"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2024.05.016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To explore the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) of the breast.

Methods: The clinical data of 28 DLBCL patients admitted to Shanxi Provincial Cancer Hospital from January 2013 to January 2023 were retrospectively analysed, including 13 cases of primary breast DLBCL (PB-DLBCL) and 15 cases of secondary breast DLBCL (SB-DLBCL), and the data of their clinical manifestations, laboratory tests, pathological examinations, treatment protocols, and follow-up were statistically analyzed.

Results: There were significant differences in IPI score, LDH level and β₂- microglobulin between PB-DLBCL and SB-DLBCL patients (P < 0.05). Among the 23 patients with breast DLBCL who received regular treatment, 13 patients achieved complete remission (9 patients with PB-DLBCL and 4 patients with SB-DLBCL) after initial treatment. By the end of follow-up, 11 patients relapsed or progressed (5 patients with PB-DLBCL and 6 patients with SB-DLBCL) and 9 patients died (3 patients with PB-DLBCL and 6 patients with SB-DLBCL). The 5-year OS rate was (75.0±15.3)% in PB-DLBCL group and (32.3±17.1)% in SB-DLBCL group. The 5-year PFS rate was （59.1±19.8）% in PB-DLBCL and 0% in SB-DLBCL group. The 5-year OS rate and PFS rate of PB-DLBCL patients were higher than those of SB-DLBCL patients (P < 0.05); the 5-year OS rate of the combined central preventive treatment group was higher than that of the chemotherapy group (P < 0.05).

Conclusion: Breast DLBCL is divided into two categories: PB-DLBCL and SB-DLBCL. Compared with SB-DLBCL, PB-DLBCL has the characteristics of lower IPI score, LDH, and β₂-microglobulin levels. PB-DLBCL patients have a longer survival period. In addition, the prognosis of patients receiving central preventive treatment is more optimistic.

查看原文本刊更多论文

[乳腺弥漫性大 B 细胞淋巴瘤患者的临床特征和预后】。］

目的探讨乳腺弥漫大B细胞淋巴瘤（DLBCL）患者的临床特征和预后：回顾性分析山西省肿瘤医院2013年1月至2023年1月收治的28例乳腺弥漫大B细胞淋巴瘤患者的临床资料，其中原发性乳腺弥漫大B细胞淋巴瘤（PB-DLBCL）13例，继发性乳腺弥漫大B细胞淋巴瘤（SB-DLBCL）15例，并对其临床表现、实验室检查、病理检查、治疗方案、随访等资料进行统计学分析：PB-DLBCL和SB-DLBCL患者的IPI评分、LDH水平和β2-微球蛋白均有明显差异（P＜0.05）。在接受正规治疗的 23 例乳腺 DLBCL 患者中，13 例患者在初始治疗后获得完全缓解（9 例 PB-DLBCL 患者和 4 例 SB-DLBCL 患者）。随访结束时，11 名患者复发或病情恶化（5 名 PB-DLBCL 患者和 6 名 SB-DLBCL 患者），9 名患者死亡（3 名 PB-DLBCL 患者和 6 名 SB-DLBCL 患者）。PB-DLBCL组的5年OS率为（75.0±15.3）%，SB-DLBCL组为（32.3±17.1）%。PB-DLBCL组的5年PFS率为（59.1±19.8）%，SB-DLBCL组为0%。PB-DLBCL患者的5年OS率和PFS率均高于SB-DLBCL患者（P＜0.05）；联合中央预防治疗组的5年OS率高于化疗组（P＜0.05）：结论：乳腺DLBCL分为两类：结论：乳腺DLBCL分为两类：PB-DLBCL和SB-DLBCL。与SB-DLBCL相比，PB-DLBCL具有IPI评分、LDH和β2-微球蛋白水平较低的特点。PB-DLBCL 患者的生存期较长。此外，接受中心预防性治疗的患者预后更乐观。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊